Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deep brain stimulation

This article was originally published in The Gray Sheet

Executive Summary

Deep brain stimulation is "a treatment option" for patients suffering from Parkinson's disease with motor complications, new guidelines from the American Academy of Neurology suggest. The April 3 release of the guidelines was welcome news to Medtronic, which manufactures Activa, one of the deep brain stimulators on the market used to treat that condition. The firm is seeking to broaden the use of Activa to treat obsessive-compulsive disorder and depression (1"The Gray Sheet" April 4, 2005, p. 16)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel